Toll-like receptor. Toll-like receptors (TLRs) are one of the largest and best-studied families of pattern-recognition receptors of the innate immune system. TLRs recognize pathogen- and danger ...

Feb 27, 2025 Nikhil Kaitwade Comment on Global GLP-1 Receptor Agonist Market Set for Remarkable Growth, Projected to Reach USD 72,127.79 Million by 2034 grow at a CAGR of 11.7% The global GLP-1 ...

Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.

The lead Eikon drug, EIK1001, is a small molecule designed to hit toll-like receptors 7 and 8 (TLR7/8). Activating these receptors is intended to spark an immune response that fights cancer.

However, Mounjaro belongs to a class of drugs called dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Kidney problems have been ...

Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web ...

Data submitted to the UK drugs regulator show a total of 82 deaths related to glucagon-like peptide-1 receptor agonists, the class of drugs used for weight loss and type 2 diabetes. Data from the ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...

STING/TLR-agonist Antibody-Drug Conjugates and mRNA technologies You will also have the opportunity to ask any burning questions and go back to your teams with a full picture of the innate ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

The following is a summary of “First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer,” published in the February 2025 issue ...